Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.32 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14452881 | 0.84 | AXL (0.37) | AXLNUDT1PSMD14TDP2NSD2 | |
| SCHEMBL22579802 | 0.80 | TDP1 (0.42) | CYP19A1TBXAS1DUSP10MAPK14TDP2 | |
| SCHEMBL2981867 | 0.76 | MAPK1 (0.31) | — | |
| SCHEMBL2984071 | 0.74 | HRH1 (0.40) | AXLNUDT1PSMD14SLC11A2MAPK14 | |
| SCHEMBL2993177 | 0.74 | CA1 (0.33) | — | |
| SCHEMBL9923724 | 0.73 | SMN1; SMN2 (0.39) | AXLNUDT1PSMD14TDP2NSD2 | |
| SCHEMBL3091229 | 0.69 | CES1 (0.45) | CYP19A1SLC11A2CES1TDP1 | |
| SCHEMBL1864779 | 0.69 | CHRM2 (0.45) | CYP19A1MAPK14CES1 | |
| SCHEMBL9923728 | 0.69 | AXL (0.34) | AXLNUDT1PSMD14TDP1 | |
| SCHEMBL4015467 | 0.67 | TDP2 (0.45) | CYP19A1TBXAS1MAPK14TDP2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| CN-101068781-B | Compounds for alzheimer's disease | MYRIAD GENETICS, INC. (US) | 2012-02-01 | — | — | CN | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| CN-101460164-A | Compounds for diseases and disorders | MYRIAD GENETICS INC (US) | 2009-06-17 | — | — | CN | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2010187-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| CN-101068781-A | Compounds for alzheimer's disease | MYRIAD GENETICS INC (US) | 2007-11-07 | — | — | CN | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1809601-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006041874-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | SLC18A2, SLC18A3, NLN | AXL 4803/4885NUDT1 2236/4885PSMD14 2131/4885 |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | AXL 3581/4885NUDT1 1003/4885PSMD14 3927/4885 |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | AXL 3581/4885NUDT1 1003/4885PSMD14 3927/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | AXL 3154/4885NUDT1 1345/4885PSMD14 4177/4885 |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | AXL 1793/4885NUDT1 2187/4885PSMD14 3503/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | AXL 1563/4885NUDT1 2102/4885PSMD14 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.